Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Acquires 83,807 Shares

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi bought 83,807 shares of Tiziana Life Sciences stock in a transaction that occurred on Tuesday, August 4th. The shares were acquired at an average cost of $0.97 per share, with a total value of $81,292.79. Following the acquisition, the chief executive officer owned 4,556,068 shares of the company’s stock, valued at $4,419,385.96. The trade was a 1.87% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi purchased 237,616 shares of Tiziana Life Sciences stock. The stock was acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00.
• On Monday, August 3rd, Ivor Elrifi acquired 667,000 shares of Tiziana Life Sciences stock. The shares were bought at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Stock Performance

Shares of TLSA opened at $0.97 on Friday. Tiziana Life Sciences Ltd has a 52 week low of $0.87 and a 52 week high of $2.53. The stock’s 50-day moving average price is $1.14 and its 200-day moving average price is $1.30.

Institutional Investors Weigh In On Tiziana Life Sciences

A number of hedge funds have recently modified their holdings of the company. Zhang Financial LLC increased its holdings in shares of Tiziana Life Sciences by 12.0% during the 1st quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock worth $131,000 after buying an additional 12,000 shares during the last quarter. Marshall Wace LLP lifted its holdings in Tiziana Life Sciences by 5.2% in the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock valued at $420,000 after acquiring an additional 14,005 shares during the last quarter. Rachor Investment Advisory Services LLC purchased a new position in Tiziana Life Sciences in the fourth quarter worth approximately $25,000. Cubist Systematic Strategies LLC purchased a new position in Tiziana Life Sciences in the first quarter worth approximately $25,000. Finally, HRT Financial LP acquired a new stake in Tiziana Life Sciences during the fourth quarter worth $36,000.

Wall Street Analysts Forecast Growth

TLSA has been the subject of a number of analyst reports. Wall Street Zen cut Tiziana Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Finally, Weiss Ratings downgraded Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Tiziana Life Sciences currently has an average rating of “Reduce”.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small?molecule program, milciclib, is an oral cyclin?dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.